These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 16619108)

  • 61. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
    Reboldi G; Angeli F; Cavallini C; Gentile G; Mancia G; Verdecchia P
    J Hypertens; 2008 Jul; 26(7):1282-9. PubMed ID: 18550998
    [TBL] [Abstract][Full Text] [Related]  

  • 62. RAAS inhibition/blockade in patients with cardiovascular disease: implications of recent large-scale randomised trials for clinical practice.
    Pitt B
    Heart; 2009 Aug; 95(15):1205-8. PubMed ID: 19401281
    [No Abstract]   [Full Text] [Related]  

  • 63. ONTARGET proves telmisartan efficacy compared to ramipril in cardiovascular protection of patients at high risk and without heart failure.
    Cardiovasc J Afr; 2008; 19(2):108-9; discussion 109-10. PubMed ID: 18516357
    [No Abstract]   [Full Text] [Related]  

  • 64. The use of secondary medical prevention after primary vascular reconstruction: studies on usage and effectiveness.
    Høgh AL
    Dan Med J; 2012 Sep; 59(9):B4514. PubMed ID: 22951205
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Absence of association between angiotensin I-converting enzyme (ACE) DD genotype and the frequency of ACE inhibitor therapy.
    Sigusch HH; Surber R; Vogt S; Müller S; Hoffmann A
    Pharmazie; 1997 Jul; 52(7):565-6. PubMed ID: 9266596
    [No Abstract]   [Full Text] [Related]  

  • 66. Using ACE inhibitors appropriately.
    Bicket DP
    Am Fam Physician; 2002 Aug; 66(3):461-8. PubMed ID: 12182524
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Blood pressure and cardiovascular risk in the HOPE study.
    Taylor R
    Lancet; 2002 Jun; 359(9323):2117-8; author reply 2118. PubMed ID: 12086795
    [No Abstract]   [Full Text] [Related]  

  • 68. [Should normotensive diabetic patients with microalbuminuria be treated with angiotensin converting enzyme inhibitors?].
    Feldt-Rasmussen BF
    Ugeskr Laeger; 2002 Apr; 164(14):1907-9. PubMed ID: 11957423
    [No Abstract]   [Full Text] [Related]  

  • 69. Prevention of cardiovascular disease: an evidence-based clinical aid 2004.
    Fulcher GR; Amarena JV; Conner GW; Gilbert RE; Hankey GJ;
    Med J Aust; 2004 Sep; 181(S6):S1-S14. PubMed ID: 15377260
    [No Abstract]   [Full Text] [Related]  

  • 70. Implications from the Heart Outcomes Prevention Evaluation Study.
    Weir MR; Blantz RC
    Curr Opin Nephrol Hypertens; 2001 Jan; 10(1):61-3. PubMed ID: 11195053
    [No Abstract]   [Full Text] [Related]  

  • 71. Behavioral issues in the efficacy versus effectiveness of pharmacologic agents in the prevention of cardiovascular disease.
    Pearson TA; Feinberg W
    Ann Behav Med; 1997; 19(3):230-8. PubMed ID: 9603698
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [ACE inhibitors in cardiovascular diseases symposium. Colon, January 1994].
    Z Kardiol; 1994; 83 Suppl 4():1-87. PubMed ID: 7856275
    [No Abstract]   [Full Text] [Related]  

  • 73. New clinical trials of angiotensin blockade in cardiovascular disease: foreword.
    Julius S
    Am J Hypertens; 2000 May; 13(5 Pt 2):55S-56S. PubMed ID: 10830789
    [No Abstract]   [Full Text] [Related]  

  • 74. The influence of mortality trials on the evolution of clinical practice.
    Sleight P
    Cardiology; 1994; 84(6):413-9. PubMed ID: 8062307
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Secondary cardiovascular risk prevention--we can do better.
    Brekke M; Gjelsvik B
    Lancet; 2009 Mar; 373(9667):873-5. PubMed ID: 19286069
    [No Abstract]   [Full Text] [Related]  

  • 76. Treatment B) drug therapy: executive summary of the Japan Atherosclerosis Society(JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan--2012 version.
    Teramoto T; Sasaki J; Ishibashi S; Birou S; Daida H; Dohi S; Egusa G; Hiro T; Hirobe K; Iida M; Kihara S; Kinoshita M; Maruyama C; Ohta T; Okamura T; Yamashita S; Yokode M; Yokote K
    J Atheroscler Thromb; 2013; 20(12):850-60. PubMed ID: 24335039
    [No Abstract]   [Full Text] [Related]  

  • 77. Pragmatic and mechanistic trials.
    Califf RM; Woodlief LH
    Eur Heart J; 1997 Mar; 18(3):367-70. PubMed ID: 9076373
    [No Abstract]   [Full Text] [Related]  

  • 78. Audit of use of ACE inhibitors and monitoring in general practice. Guidelines on monitoring, on their own, are not sufficient.
    Freemantle N; Mason J; Eccles M
    BMJ; 1999 Jun; 318(7199):1697. PubMed ID: 10373186
    [No Abstract]   [Full Text] [Related]  

  • 79. [Novel European recommendations on prevention of cardiovascular diseases caused by atherosclerosis].
    Perova NV
    Kardiologiia; 2004; 44(1):76-82. PubMed ID: 15137379
    [No Abstract]   [Full Text] [Related]  

  • 80. Current concerns and difficulties in the prevention of cardiovascular diseases.
    Rallidis LS; Anastasiou-Nana MI
    Hellenic J Cardiol; 2011; 52(5):437-41. PubMed ID: 21940291
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.